Latest Insider Transactions at Unicycive Therapeutics, Inc. (UNCY)
This section provides a real-time view of insider transactions for Unicycive Therapeutics, Inc. (UNCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Unicycive Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Unicycive Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 09
2024
|
Gaurav Aggarwal Director |
BUY
Conversion of derivative security
|
Indirect |
5,500,000
+35.55%
|
-
|
Jul 11
2023
|
Gaurav Aggarwal Director |
BUY
Conversion of derivative security
|
Indirect |
3,470,152
+50.0%
|
-
|
Jul 11
2023
|
Douglas Jermasek EVP of Corporate Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
104,612
+37.41%
|
-
|
Jul 11
2023
|
Pramod Gupta EVP, Pharmaceuticals and BD |
BUY
Exercise of conversion of derivative security
|
Direct |
41,845
+50.0%
|
-
|
Jul 11
2023
|
Shalabh K. Gupta CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
104,612
+3.97%
|
-
|
Jul 15
2022
|
Brigitte Schiller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
26,738
+50.0%
|
-
|
May 16
2022
|
Brigitte Schiller Director |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$0
$0.82 P/Share
|